Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS I)

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00530348
First received: September 13, 2007
Last updated: November 17, 2014
Last verified: November 2014
Results First Received: November 17, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Treatment
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab
Biological: Interferon beta-1a

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were screened at 101 investigational sites in Argentina, Australia, Brazil, Canada, Croatia, the Czech Republic, France, Germany, Mexico, Poland, Russia, Serbia, Sweden, Ukraine, the United Kingdom (UK), and the United States (US) between August 28, 2007 and April 27, 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Interferon Beta-1a Interferon beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Alemtuzumab Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.

Participant Flow:   Overall Study
    Interferon Beta-1a     Alemtuzumab  
STARTED     195 [1]   386 [1]
Treated     187 [2]   376 [2]
COMPLETED     173     367  
NOT COMPLETED     22     19  
Adverse Event                 5                 1  
Death                 0                 1  
Lack of Efficacy                 2                 0  
Lost to Follow-up                 0                 2  
Physician Decision                 1                 2  
Pregnancy                 1                 0  
Withdrawal by Subject                 12                 12  
Randomised in error                 1                 0  
Noncompliance with inclusion criterion 3                 0                 1  
[1] Randomized.
[2] All randomized participants who received at least 1 dose of study drug.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study drug.

Reporting Groups
  Description
Interferon Beta-1a Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Alemtuzumab Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
Total Total of all reporting groups

Baseline Measures
    Interferon Beta-1a     Alemtuzumab     Total  
Number of Participants  
[units: participants]
  187     376     563  
Age  
[units: years]
Mean ± Standard Deviation
  33.2  ± 8.48     33.0  ± 8.03     33.1  ± 8.18  
Gender  
[units: participants]
     
Female     122     243     365  
Male     65     133     198  
Time Since First Relapse  
[units: years]
Mean ± Standard Deviation
  2.0  ± 1.32     2.1  ± 1.36     2.1  ± 1.35  
Number of Relapse Episodes in the Preceding 2 Years [1]
[units: participants]
     
1 Relapse     3     12     15  
2 Relapses     118     215     333  
Greater than or equal to 3 Relapses     66     149     215  
Expanded Disability Status Scale (EDSS) Score [2]
[units: units on a scale]
Mean ± Standard Deviation
  2.0  ± 0.79     2.0  ± 0.81     2.0  ± 0.81  
[1] Number of participants with 1, 2 or greater than or equal to 3 relapses are reported.
[2] EDSS is an ordinal scale in half-point increments that quantifies disability in participants with multiple sclerosis (MS). It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Sustained Accumulation of Disability (SAD)   [ Time Frame: Up to 2 years ]

2.  Primary:   Annualized Relapse Rate   [ Time Frame: Up to 2 years ]

3.  Secondary:   Percentage of Participants Who Were Relapse Free at Year 2   [ Time Frame: Year 2 ]

4.  Secondary:   Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2   [ Time Frame: Baseline, Year 2 ]

5.  Secondary:   Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2   [ Time Frame: Baseline, Year 2 ]

6.  Secondary:   Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2   [ Time Frame: Baseline, Year 2 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Trial Transparency Team
Organization: Sanofi
e-mail: Contact-us@sanofi.com


Publications:

Responsible Party: Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT00530348     History of Changes
Other Study ID Numbers: CAMMS323, ISRCTN21534255, ACTRN12608000435381, CARE-MS I, 2007-001161-14
Study First Received: September 13, 2007
Results First Received: November 17, 2014
Last Updated: November 17, 2014
Health Authority: United States: Food and Drug Administration
Brazil: National Health Surveillance Agency
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Canada: Health Canada
Croatia: Agency for Medicinal Product and Medical Devices
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Paul-Ehrlich-Institut
Mexico: Federal Commission for Protection Against Health Risks
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
Sweden: Medical Products Agency
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency